Medivation Competitors and Similar CompaniesClear all

Medivation's competitors and similar companies include CureVac, Northwest Biotherapeutics, Active Biotech and Candel Therapeutics.

	Medivation Medivation, Inc. is a biopharmaceutical company focused on the rapid development of small molecule drugs to treat serious diseases for which there are limited treatment options.	CureVac CureVac is a biotechnology company offering messenger RNA (mRNA) technology.	Northwest Biotherapeutics Northwest Biotherapeutics is a biotechnology company focused on developing and commercializing immunotherapy products to treat cancer.	Active Biotech Active Biotech is a biotechnology company with a focus on neurodegenerative and inflammatory diseases and cancer.	Candel Therapeutics Candel Therapeutics (formerly known as Advantagene) is a biopharmaceutical company developing cancer immunotherapies.
Founding Date	Founding Date 2004	Founding Date 2000	Founding Date 1998	Founding Date 1998	Founding Date 1999
Type	Type Subsidiary	Type Public	Type Public	Type Public	Type Public
Tags	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare biotech drug development oncology pharma
Locations	Locations San Francisco, US HQ Jersey, JE New York, US Washington, US	Locations Tübingen, DE HQ Ottignies Louvain La Neuve, BE Wiesbaden, DE Amsterdam, NL Basel, CH Boston, US	Locations Bethesda, US HQ	Locations Lund, SE HQ Lund, SE	Locations Needham, US HQ
Employees	Employees 62829% increase	Employees 82517% decrease	Employees 1721% increase	Employees 517% decrease	Employees 50
Valuation ($)	Valuation ($) N/A	Valuation ($) 648.3 m	Valuation ($) 349.5 m	Valuation ($) 21 m	Valuation ($) 176.8 m
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) €535.2m (FY, 2024)	Revenue (est.) $1.4m (FY, 2025)	Revenue (est.) N/A	Revenue (est.) N/A
Cost of goods	Cost of goods N/A	Cost of goods €9.7m (FY, 2024)	Cost of goods N/A	Cost of goods N/A	Cost of goods N/A
Gross profit	Gross profit N/A	Gross profit €534.4m (FY, 2024)	Gross profit N/A	Gross profit N/A	Gross profit N/A
Net income	Net income $244.7m (FY, 2015)	Net income €162.2m (FY, 2024)	Net income ($60.2m) (FY, 2025)	Net income (kr37.3m) (FY, 2025)	Net income ($38.2m) (FY, 2025)
Operating ⚠
Phase I Trials Products	Phase I Trials Products N/A	Phase I Trials Products 3 (May, 2020)	Phase I Trials Products N/A	Phase I Trials Products 2 (FY, 2020)	Phase I Trials Products N/A
Funding
Total funding raised	Total funding raised N/A	Total funding raised $ 1.1b	Total funding raised $ 135.9m	Total funding raised N/A	Total funding raised $ 64.6m